| Pfizer AG - Vyndaqel 61 mg, Weichkapseln | | 67518 | | 01 | | Vyndaqel 61 mg | | Weichkapseln | | N07XX08 | | Tafamidis | | 05.03.2020 | | |
| | Composition | | tafamidisum 61 mg, macrogolum 400, polysorbatum 20, povidonum K 90, E 321, Kapselhülle: gelatina, glycerolum, sorbitolum liquidum partim deshydricum corresp. sorbitolum max. 44 mg, E 172 (rubrum), Drucktinte: macrogolum 400, polyvinylis acetas phtalas, E 171, propylenglycolum, pro capsula. | | Packungsbestandteile | | Capsules molles | | | | | Principe actif | Concentr. |
|---|
| Tafamidisum | 61 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Tafamidisum | 61 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Rubrum) | | | | E 171 | | color. | | E 172 | | color. | | E 321 | | | | Gelatina | | Kapselhülle | | Glycerol | | | | Macrogol | 400 | Drucktinte | | Polysorbatum 20 | | | | Polyvinylis Acetas Phtalas | | | | Povidonum K | 90 | | | Pro Capsula | | | | Propylenglycol | | | | Sorbitolum Liquidum Partim Deshydricum | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 30 | 9422.28 | 9975.05 | B | LS | Oui |
|
|
